Alvotech adds Lisa Graver, Arni Hardarson, Linda McGoldrick and Ann Merchant to its Board of Directors

– ICELAND, Reykjavik – Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines, today announced the additions of Lisa Graver, Arni Hardarson, Linda McGoldrick, and Ann Merchant to its Board of Directors, as part of its transition from a private to a publicly traded company.

Ms. Merchant, Ms. McGoldrick, and Mr. Davies serve as independent directors.

“I am delighted to welcome our new members of our board at a crucial time in our evolution,” said Executive Chairman and founder, Robert Wessman. “The scientific expertise, operational experience, and capital markets acumen of the new board members will be important in supporting our mission to enhance the sustainability of the global healthcare system by expanding access to biologic medicines.”

About Linda McGoldrick

Linda McGoldrick serves as Chairman of Alvotech’s Board of Directors’ Audit Committee. She has served in numerous management and non-executive director roles in the healthcare and life sciences industries, internationally. These include leadership positions at Marsh-MMC Companies, Veos, Kaiser Permanente International, Compass Pathways, and Zillion. She founded and currently serves as Chairman and CEO of Financial Health Associates International and is the CEO of 2EnableHealth. In 2012, Ms. McGoldrick was named as one of the Top 100 Corporate Directors in Remuneration of Fortune 100 Companies by the Financial Times.

She received an MSW in Healthcare from the University of Pennsylvania and an MBA from The Wharton School.

About Lisa Graver

Lisa Graver has served in various leadership positions at Alvogen since June 2010, including as CEO of Alvogen U.S. since August 2015. Before joining Alvogen, Ms. Graver was VP of Intellectual Property and Senior Director of Intellectual Property at Actavis.

She holds a BS degree in biology from Lakehead University and a Juris Doctor degree from Case Western University School of Law.

About Arni Hardarson

Arni Hardarson is a partner in Aztiq and served as General Counsel and Deputy CEO of Alvogen and been part of Alvogen’s executive team since 2009. Before joining Aztiq and Alvogen, Mr. Hardarson was VP of Tax and Structure at Actavis and served as head of tax and legal services at Deloitte.

He holds a master’s degree in law from the University of Iceland.

About Ann Merchant

Ann Merchant has served as VP for MorphoSys since 2018 and Head of Global Supply Chain since January 2019. Before joining MorphoSys, Ms. Merchant served as President of Schreiner Medpharm and held various roles at Amgen, including VP Head of International Supply Chain.

She holds an MBA from Henley Business School and a BS degree in languages from Georgetown University.

About Alvotech

Alvotech specializes in making biosimilars, to improve lives by expanding access to affordable biologic medicines. Founded by Robert Wessman, Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective biologics, enabled by a vertically integrated approach from R&D to fill and finish manufacturing. To enable global reach, Alvotech has formed a network of strategic commercial partnerships in over 90 countries, including the United States, Canada, Europe, Asia, Latin America, Africa, and the Middle East. Alvotech’s current portfolio of eight biosimilars and biosimilar candidates, includes AVT02, a biosimilar to Humira which is approved and marketed in Europe and Canada, and seven biosimilar candidates targeting immunology, oncology, respiratory, bone disease, and ophthalmology.

For more information: https://www.alvotech.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team